Trial Profile

A Phase 1b, Open-label, Pilot Study of CLN-978 Administered Subcutaneously for the Treatment of Moderate to Severe Systemic Lupus Erythematosus (SLE)

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 04 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CLN 978 (Primary)
Indications Systemic lupus erythematosus
Focus Adverse reactions

Most Recent Events

27 Feb 2025 According to Cullinan Therapeutics media release, the company announced that initial clinical data from this global Phase 1 study of CLN-978 is expected in Q4 2025.
29 Jan 2025 Planned initiation date changed from 1 Dec 2024 to 1 Jan 2025.
12 Dec 2024 Planned initiation date changed from 1 Nov 2024 to 1 Dec 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com